Literature DB >> 8409682

Lack of prognostic value of immunoreactivity for p62 oncoprotein in colorectal carcinoma.

K Matsumoto1, J Yamamoto, T Miura.   

Abstract

Immunohistochemical staining for c-myc p62 oncoprotein (p62) was performed in 59 colorectal carcinomas using mouse monoclonal antibody against human c-myc protein (MYC1-6E10). The immunoreactivity for p62 was intense in 22 (37.3%), and weak in 37 (62.7%) of the tumors. Advanced disease and nodal metastasis were more frequently seen in tumors showing intense staining but the difference did not reach statistical significance. Sixteen patients have died of the disease but overall survival rates did not differ between patients with tumors showing intense staining and those with tumors showing weakly staining. In 50 patients undergoing grossly curative resection, local or distant metastasis developed in 15 patients. Immunoreactivity for p62 had no effect on the rate of recurrence or disease free survival rates in these 50 patients undergoing grossly curative resection. The present study revealed that the immunoreactivity for p62 had no prognostic value in colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8409682     DOI: 10.1007/bf00299337

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  10 in total

Review 1.  Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour.

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1991-11       Impact factor: 7.996

2.  Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance.

Authors:  M Gutman; Y Ravia; D Assaf; T Yamamoto; R Rozin; Y Shiloh
Journal:  Int J Cancer       Date:  1989-11-15       Impact factor: 7.396

3.  Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma.

Authors:  K Alitalo; M Schwab; C C Lin; H E Varmus; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

4.  Expression of the myc gene family in different stages of human colorectal cancer.

Authors:  G G Finley; N T Schulz; S A Hill; J R Geiser; J M Pipas; A I Meisler
Journal:  Oncogene       Date:  1989-08       Impact factor: 9.867

5.  Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease.

Authors:  M J Cline; H Battifora; J Yokota
Journal:  J Clin Oncol       Date:  1987-07       Impact factor: 44.544

6.  Expression of cellular oncogenes in human malignancies.

Authors:  D J Slamon; J B deKernion; I M Verma; M J Cline
Journal:  Science       Date:  1984-04-20       Impact factor: 47.728

7.  Association of genetic alterations of c-myc, c-fos, and c-Ha-ras proto-oncogenes in colorectal tumors. Frequency and clinical significance.

Authors:  M A Nagai; A Habr-Gama; C T Oshima; M M Brentani
Journal:  Dis Colon Rectum       Date:  1992-05       Impact factor: 4.585

8.  Expression of c-myc gene product in gastric carcinoma.

Authors:  I Ninomiya; Y Yonemura; H Matsumoto; K Sugiyama; T Kamata; K Miwa; I Miyazaki; H Shiku
Journal:  Oncology       Date:  1991       Impact factor: 2.935

9.  c-myc oncogene product expression and prognosis in operable breast cancer.

Authors:  A P Locker; C S Dowle; I O Ellis; C W Elston; R W Blamey; K Sikora; G Evan; R A Robins
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

10.  Detection of the c-myc oncogene product in colonic polyps and carcinomas.

Authors:  J Stewart; G Evan; J Watson; K Sikora
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

  10 in total
  1 in total

1.  Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.